The effect of medroxyprogesterone acetate and norethisterone on the estradiol stimulated proliferation in MCF-7 cells: comparison of continuous combined versus sequential combined estradiol/progestin treatment

Objective: Little is known on the type of progestin and regimen type in relation to breast cancer risk. We have compared the effect of medroxyprogesterone acetate (MPA) and norethisterone (NET) on the estradiol stimulated proliferation in MCF-7 cells with respect to different regimens used in combined hormone replacement therapy (HRT).

Design: To approximate the in vivo conditions in HRT, MCF-7 cultures were pretreated with estradiol followed by estradiol/progestin treatment to represent the sequential combined model and compared with non pretreated cultures followed by estradiol/progestin treatment for the continuous combined model.

Results: When using progestins in the continuous combined form with estradiol (10(-10) M) both progestins showed a significant reduction in the estradiol stimulated proliferation of the MCF-7 cells. In the sequential combined model the addition of MPA led to a stronger significant reduction of MCF-7 proliferation but in a narrower concentration range (from 10(-8) to 10(-6) M) compared to the continuous treatment. NET did not show any significant effect on proliferation in the SC model.

Conclusion: Different regimen types and different progestins do lead to significantly different effects on the proliferation of a breast cancer cell line. These findings might be useful in the elucidation of potential mechanisms involved in the clinical situation.

Hormone replacement therapy; Medroxyprogesterone acetate; Norethisterone; MCF-7 cells; Regimen types

[1] Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., Hoover R.: "Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk". JAMA, 2000, 283, 485.

[2] Ross R. K., Paganini-Hill A., Wan P. C., Pike M. C.: "Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin". J. Natl. Cancer Inst., 2000, 92, 328.

[3] Magnusson C., Baron J. A., Correia N., Bergstrom R., Adami H O., Persson I.: "Breast-cancer risk following long-term oestrogenand oestrogen-progestin-replacement therapy". Int. J. Cancer, 1999, 81, 339.

[4] Soule H. D., Vazquez J., Long A., Albert S., Brennan M.: "A human cell line from a pleural effusion derived from a breast carcinoma". J. Natl. Cancer Inst., 1973, 51, 1409.

[5] Pourreau-Schneider N., Martin P. M.. Charpin C.,J acquemier J., Saez S., Nandi S.: "How culture conditions modulate the morphofunctional differentiation of the human estradiol-sensitive mammary cell line (MCF-7)". J. Steroid. Biochem., 1984, 20, 407.

[6] Saceda M., Lippman M. E., Chambon P., Lindsey R. L., Ponglikitmongkol M., Puente M., Martin M. B.: "Regulation of the estrogen receptor in MCF-7 cells by estradiol". Mal. Endocrinology, 1988, 2, 1157.

[7] Katzenellenbogen B. S., Kendra K. L., Norman M. J., Bertho1s Y.: "Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term ab sense of estrogens". Cancer Res., 1987, 47, 4355.

[8] Schoonen W. G. E. J.、Joosten J. W. H., Klooosterboer H.J.: "Effects of two classes of progestagens pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: I MCF-7 cell lines". J. Ster. Biochem. Mal. Biol., 1995, 55, 423.

[9] Kueng W., Silber E., Eppenberger U.: "Quantification of cells cultured on 96-well plates". Anal. Biochem., 1989, 82, 16.

[10] Collaborative Group on Hormonal Factors in Breast Cancer: "Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer". Lancet, 1997, 350, 1047.

[11] Ewertz M.: "Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark". Int. J. Cancer, 1988, 42, 832.

[12] Husmann F.: "Hormone und Krebs: in wieweit erhi:ihen Estradiol und insbesondere Testosteron das Mammakarzinom-Risiko". Gyne., 1998, 11, 293.

[13] Doihara H., Takashima S., Saeki H., Takiyama W., Kurita A., Soga H. et al.: "Effect of medroxyprogesterone acetate on the cell kinetics in primary breast cancer". Gon To Kagaku Ryoho, 1990, 17, 2057.

[14] Sugiyama K., Shimizu M., Akiyama T., Ishida H., Okabe M., Tamaoki T., Akinaga S.: "Combined effect of navelbine with medroxyprogesterone acetate against human breast carcinoma MCF-7 cells in vitro". Brit. J. Cancer, 1998, 77, 1737.

[15] Sutherland R. L., HaII R. E., Pang G. Y., Musgrove E. A., Clarke C. L.: "Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary cell". Cancer Res., 1988, 48, 5084.

[16] Cline J. M., Soderqvist G., von Schoultz E., Skoog L., von Schoultz B.: "Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques". Am. J. Obstet. Gynecol., 1996, 174, 93.

[17] Hofseth L. J., Raafat A. M., Osuch J. R., Pathak D. R., Slomski C A., Haslam S. Z.: "Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast". J. Clin. Endocrin. Metab., 1999, 84, 4559.

[18] Catherino W. H.,J eng M. H.,J ordan V. C.: "Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism". Br. J. Cancer, 1993, 67, 945.

[19] Jeng M. H.,J ordan V. C.: "Growth stimulation and differential regulation of transforming growth factor-BI (TGFB I), TGFB2, and TGFB3 messenger RNA levels by norethindrone in MCF-7 human breast cancer cells". Mol. Endocr., 1991, 5, 1120.

[20] Clave! B., Pichon M. F., Pallud C., Milgrom E.: "Estradiol and progesterone receptors content and response to norethisterone treatment in advanced breast cancer". Eur. J. Cancer Clin. Oncol., 1982,18, 821.

[21] Svensson L. 0.,J ohnson S. H., Olsson S. E.: "Plasma concentrations of medroxyprogesterone acetate, estradiol and estrone following oral administraton of Klimaxil®, Trisequence®/Provera®, and Divina®. A randomised, single-blind, triple cross-over bioavailabilily study in menopausal women". Maturitas, 1994, 18, 229.

[22] Stanczyk F. Z., Brenner P. F., Mishell D. R., Ortiz A., Gentzschem E. K. E., Goebelsmann U.: "A radioimmunoassay for norethindrone (NET): measurement of serum net concentrations following ingestion of NET-containing oral contraceptive steroids". Contraception, 1978, 18, 615.

[23] Blossey H. C., Wander H. E., Koebberling J., Nagel G. A.: "Pharmakokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high dose medroxyprogesterone acetate". Cancer, 1984, 54, 1208.

[24] Klehr-Bathmann I., Kuhl H.: "Formation of ethinylestradiol in postmenopausal women during continuous treatment with a combination of estradiol, estriol and norethisterone acetate". Maturitas, 1995, 21, 245.

[25] Andreasen E. E., Madsen L. G.. Jensen H. K.: "Absorption of norethisterone acetate from tablets with normal and coarse particle size". Ugeskr Laeger, 1989, 151, 1109.

[26] Grady T., Gebretsadik T., Kerlikowske L., Ernster V., Petitti D. "Hormone replacement therapy and endometrial cancer risk: A metaanalysis". Obstet. Gynecol., 1995, 85, 304

[27] Persson I., Adami H. 0., Berkvist L., Lindgren A., Petterson B: "Hoover Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study". BMJ, 1989, 298, 147.